Back to top
more

Marinus Pharmaceuticals (MRNS)

(Real Time Quote from BATS)

$1.46 USD

1.46
297,443

+0.03 (2.10%)

Updated Jul 22, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

by Zacks Equity Research

Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.

Ultragenyx (RARE) Posts New Data From Bone Disease Study

by Zacks Equity Research

Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.

SAGE's Huntington's Disease Study Meets Primary Endpoint

by Zacks Equity Research

The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.

AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag

by Zacks Equity Research

The FDA grants priority review to AstraZeneca's (AZN) Tagrisso for treating patients with unresectable, stage III EGFR-mutated lung cancer. A decision is due in the fourth quarter of 2024.

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

by Zacks Equity Research

Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

by Zacks Equity Research

Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.

Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

by Zacks Equity Research

Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

by Zacks Equity Research

Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

by Zacks Equity Research

Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.

Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

by Zacks Equity Research

Sales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

by Zacks Equity Research

Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

by Zacks Equity Research

Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.

Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08

by Zacks Equity Research

The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.

Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk

by Zacks Equity Research

Esperion's (ESPR) Nilemdo & Nustendi get the European Commission's nod for label expansion based on data from the CLEAR Outcomes study.

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

by Zacks Equity Research

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

by Zacks Equity Research

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

by Zacks Equity Research

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.